Tapan Maniar
Chief Medical Officer Oblenio Bio
Tapan is a Physician-Executive with over 15 years of industry experience spanning early discovery through commercial launches. Tapan served as Global Development Lead for Blincyto, at Amgen, when it became the first bispecific antibody therapy approved by FDA in 2014 and EMA in 2015. He most recently served as CMO at Avencell inc, where he led a 25-member clinical team developing switchable Allogeneic CAR-T therapies for AML and played a key role in securing a $115M Series B financing. At Atara Biotherapeutics he helped advance the first commercially approved Allogeneic cell therapy platform and built the first cell therapy program in autoimmune disease, for MS. At Dragonfly he directed a phase 1 cytokine program that was successfully partnered with BMS.
Tapan earned his BA in English Literature from Northwestern University and his MD from the University of Pennsylvania School of Medicine where he also completed a fellowship in Hematology-Oncology.
Seminars
- What is the remaining first-in-class opportunity for bispecifics/multispecifics in cancer? Where do engagers fit into different lines of treatment and relapsed or resistant patients?
- How are bispecifics/multispecific formats and targets being optimized to expand applications across a breadth of solid tumors beyond blood cancer?
- Understanding how bispecifics/multispecifics can accelerate into clinical trials more quickly in the oncology setting, how this drug modality fits into the broader continuum of care for cancer, and how this translates into remaining market opportunity for cancer
- Developing or repurposing bispecifics/multispecifics for immunology to achieve sustained immune cell depletion and recognizing the different risk-benefit profiles in cancer versus immunology
- Recognizing the higher benchmark for safety data in the immunology/autoimmune disease setting compared to oncology
- Achieving deeper, more complete disease control by dual targeting of CD19 and BCMA to deplete the full spectrum of pathological B cells driving autoimmunity
- Maximizing therapeutic window and clinical potential through tri specific TCE engineering that balances potency and safety across CD19, BCMA and CD3
- Accelerating translation into the clinic by positioning dual targeting TCEs as a differentiated path toward durable immune reset in severe autoimmune disease
